全文获取类型
收费全文 | 165篇 |
免费 | 8篇 |
国内免费 | 7篇 |
专业分类
电工技术 | 1篇 |
化学工业 | 102篇 |
金属工艺 | 7篇 |
机械仪表 | 5篇 |
建筑科学 | 6篇 |
轻工业 | 8篇 |
无线电 | 13篇 |
一般工业技术 | 9篇 |
冶金工业 | 13篇 |
原子能技术 | 5篇 |
自动化技术 | 11篇 |
出版年
2023年 | 3篇 |
2022年 | 51篇 |
2021年 | 37篇 |
2020年 | 8篇 |
2019年 | 4篇 |
2018年 | 4篇 |
2017年 | 1篇 |
2016年 | 3篇 |
2015年 | 4篇 |
2014年 | 8篇 |
2013年 | 6篇 |
2012年 | 7篇 |
2011年 | 18篇 |
2010年 | 1篇 |
2009年 | 6篇 |
2008年 | 2篇 |
2007年 | 1篇 |
2006年 | 2篇 |
2005年 | 5篇 |
2004年 | 1篇 |
2003年 | 2篇 |
2002年 | 2篇 |
2001年 | 1篇 |
1999年 | 1篇 |
1996年 | 1篇 |
1986年 | 1篇 |
排序方式: 共有180条查询结果,搜索用时 0 毫秒
31.
The general chemotherapy for Peripheral T-cell lymphoma (PTCL) featuring an active invasion has less curative effect and worse prognosis in comparison with that for B-cell non-Hodgkin's lymphoma (NHL). Studies in recent years suggest that hematopoietic stem cell transplantation (HSCT) has better curative effect on the PTCL; however, it is significant to do more studies on some aspects such as the methodology, punctuality, preconditioning, and pretreatment intensity of the transplantation, which are crucial to the curative effect. 相似文献
32.
Wang Y Shen D Wang VM Sen HN Chan CC 《International journal of molecular sciences》2011,12(9):5684-5697
Primary vitreoretinal lymphoma (PVRL) or primary intraocular lymphoma, a subtype of primary central nervous system lymphoma, often masquerades as uveitis. The diagnosis of PVRL requires identification of lymphoma cells inside the eye, which is often challenging due to the frequent necrosis and admixing of PVRL cells with reactive lymphocytes. Therefore, detection of immunoglobulin heavy chain (IgH) and T-cell receptor (TCR) gene rearrangements provide molecular diagnosis of B- and T-cell lymphoma, respectively. We retrospectively evaluated 208 cases with a clinical diagnosis of masquerade syndrome from 1998 to 2010. In 200 cases with molecular analyses using microdissection and polymerase chain reaction, we found that 110 cases had IgH gene rearrangement, 5 cases had TCR gene rearrangement, and 85 cases were negative for these two gene arrangements. The molecular data corroborated the cytopathological diagnoses of PVRL and uveitis in the majority of cases. Cytokine above the detected levels in the specimens were also measured in 80 of the 208 cases. A ratio of vitreous IL-10 to IL-6 greater than 1, suggesting PVRL, was found in 56/80 cases; 53/56 had the correct diagnosis. A ratio less than 1, suggesting uveitis, was found in 24/80 cases; 17/24 correctly confirmed the diagnosis. Moreover, the molecular data corresponded well with the clinical course of the diseases. The sensitivity and specificity of these molecular biomarkers for the diagnosis of PVRL are higher than 95%. 相似文献
33.
目的: 探讨 P16 基因纯合性缺失与非何杰金氏淋巴瘤 (NHL) 的关系及其临床意义。 方法: 采用半定量多重 PCR检测了 51 例非何杰金氏淋巴瘤病人P16 基因纯合性缺失情况。结果: 发现 9 例病人出现 P16 基因纯合性缺失, 缺失率为 17.6%, 且低度恶性组与高度恶性组有显著性差异(P <0.05)。 结论: P16 基因纯合性缺失主要发生于恶性程度较高的NHL 中, 可作为判断 NHL 恶性程度高低和决定NHL 治疗策略的一个参考指标。 相似文献
34.
Audrey L. Smith Alexandria P. Eiken Sydney A. Skupa Dalia Y. Moore Lelisse T. Umeta Lynette M. Smith Elizabeth R. Lyden Christopher R. DAngelo Avyakta Kallam Julie M. Vose Tatiana G. Kutateladze Dalia El-Gamal 《International journal of molecular sciences》2022,23(12)
B-cell chronic lymphocytic leukemia (CLL) results from intrinsic genetic defects and complex microenvironment stimuli that fuel CLL cell growth through an array of survival signaling pathways. Novel small-molecule agents targeting the B-cell receptor pathway and anti-apoptotic proteins alone or in combination have revolutionized the management of CLL, yet combination therapy carries significant toxicity and CLL remains incurable due to residual disease and relapse. Single-molecule inhibitors that can target multiple disease-driving factors are thus an attractive approach to combat both drug resistance and combination-therapy-related toxicities. We demonstrate that SRX3305, a novel small-molecule BTK/PI3K/BRD4 inhibitor that targets three distinctive facets of CLL biology, attenuates CLL cell proliferation and promotes apoptosis in a dose-dependent fashion. SRX3305 also inhibits the activation-induced proliferation of primary CLL cells in vitro and effectively blocks microenvironment-mediated survival signals, including stromal cell contact. Furthermore, SRX3305 blocks CLL cell migration toward CXCL-12 and CXCL-13, which are major chemokines involved in CLL cell homing and retention in microenvironment niches. Importantly, SRX3305 maintains its anti-tumor effects in ibrutinib-resistant CLL cells. Collectively, this study establishes the preclinical efficacy of SRX3305 in CLL, providing significant rationale for its development as a therapeutic agent for CLL and related disorders. 相似文献
35.
36.
Asami Nishikori Yoshito Nishimura Rei Shibata Koh-ichi Ohshima Yuka Gion Tomoka Ikeda Midori Filiz Nishimura Tadashi Yoshino Yasuharu Sato 《International journal of molecular sciences》2021,22(8)
Immunoglobulin G4-related disease (IgG4-RD) is a systemic disorder characterized by tissue fibrosis and intense lymphoplasmacytic infiltration, causing progressive organ dysfunction. Activation-induced cytidine deaminase (AID), a deaminase normally expressed in activated B-cells in germinal centers, edits ribonucleotides to induce somatic hypermutation and class switching of immunoglobulin. While AID expression is strictly controlled under physiological conditions, chronic inflammation has been noted to induce its upregulation to propel oncogenesis. We examined AID expression in IgG4-related ophthalmic disease (IgG4-ROD; n = 16), marginal zone lymphoma with IgG4-positive cells (IgG4+ MZL; n = 11), and marginal zone lymphoma without IgG4-positive cells (IgG4- MZL; n = 12) of ocular adnexa using immunohistochemical staining. Immunohistochemistry revealed significantly higher AID-intensity index in IgG4-ROD and IgG4+ MZL than IgG4- MZL (p < 0.001 and = 0.001, respectively). The present results suggest that IgG4-RD has several specific causes of AID up-regulation in addition to inflammation, and AID may be a driver of oncogenesis in IgG4-ROD to IgG4+ MZL. 相似文献
37.
Ki Young Choi Santiago Correa Jouha Min Jiahe Li Sweta Roy Kristiana H. Laccetti Erik Dreaden Stephanie Kong Roun Heo Young Hoon Roh Edward C. Lawson Peter A. Palmer Paula T. Hammond 《Advanced functional materials》2019,29(20)
Using siRNA therapeutics to treat hematologic malignancies has been unsuccessful because blood cancer cells exhibit remarkable resistance to standard transfection methods. Herein, the successful delivery of siRNA therapeutics with a dual‐targeted, layer‐by‐layer nanoparticle (LbL‐NP) is reported. The LbL‐NP protects siRNA from nucleases in the bloodstream by embedding it within polyelectrolyte layers that coat a polymeric core. The outermost layer consists of hyaluronic acid (a CD44‐ligand) covalently conjugated to CD20 antibodies. The CD20/CD44 dual‐targeting outer layer provides precise binding to blood cancer cells, followed by receptor‐mediated endocytosis of the LbL‐NP. This siRNA delivery platform is used to silence B‐cell lymphoma 2 (BCL‐2), a pro‐survival protein, in vitro and in vivo. The dual‐targeting approach significantly enhances internalization of BCL‐2 siRNA in lymphoma and leukemia cells, which leads to significant downregulation of BCL‐2 expression. Systemic administration of the dual‐targeted, siRNA‐loaded nanoparticle induces apoptosis and hampers proliferation of blood cancer cells, both in cell culture and in orthotopic non‐Hodgkin's lymphoma animal models. These results provide the basis for approaches to targeting blood‐borne cancers and other diseases and suggest that LbL nanoassemblies are a promising approach for delivering therapeutic siRNA to hematopoetic cell types that are known to evade transfection by other means. 相似文献
38.
Schlapschy M Gruber H Gresch O Schäfer C Renner C Pfreundschuh M Skerra A 《Protein engineering, design & selection : PEDS》2004,17(12):847-860
CD30, the so-called Reed-Sternberg antigen, constitutes a promising cell-specific target for the treatment of Hodgkin's lymphoma. Starting from the previously characterized cognate HRS3 mouse monoclonal antibody, the bacterially produced functional Fab fragment was humanized by grafting the CDRs from the mouse antibody framework on to human immunoglobulin consensus sequences. This procedure led to a 10-fold decreased antigen affinity, which surprisingly was found to be mainly due to the VH domain. To improve the antigen-binding activity, an in vitro evolution strategy was employed, wherein random mutations were introduced into the humanized VH domain by means of error-prone PCR, followed by a filter sandwich Escherichia coli colony screening assay for functional Fab fragments using a recombinant extracellular domain of the CD30 antigen. After three cycles of in vitro affinity maturation, the optimized Fab fragment huHRS3-VH-EP3/1 was identified, which carried four exchanged residues within or close to the VH CDRs and had an affinity that was almost identical with that of the murine HRS3 Fab fragment. The resulting humanized Fab fragment was fully functional with respect to CD30 binding both in ELISA with the recombinant antigen and in FACS experiments with CD30-positive L540CY cells. In the light of the previously successful clinical application of an alphaCD30 x alphaCD16 bispecific mouse quadroma antibody derived from HRS3, the humanized Fab fragment comprises an important step towards the construction of a fully recombinant therapeutic agent. The combination of random mutagenesis and colony filter screening assay that was successfully applied here should be generally useful as a method for the rapid functional optimization of humanized antibody fragments. 相似文献
39.
淋巴瘤是源于淋巴造血系统的一类恶性肿瘤,基于医学影像及病理图像的精准诊断对临床治疗淋巴瘤具有重要价值。随着机器学习和深度学习技术的发展,利用人工智能技术对淋巴瘤图像分类已成为医学领域的研究热点之一。对淋巴瘤影像及病理图像分类技术的研究进展进行了系统总结与分析,并重点阐述了基于机器学习等新技术的图像分类方法与研究概况,对淋巴瘤图像分类的相关技术做了总结与展望。 相似文献
40.
Immunotherapy has transformed the treatment of hematologic malignancies in the past two decades. The treatment of acute lymphoblastic leukemia (ALL), in particular, has been highly impacted by multiple novel immunotherapies. For pediatric patients with T-cell malignancies, translating immunotherapies has proved more challenging due to the complexities of fratricide, risk of product contamination with malignant cells, and concerns over T-cell aplasia. Despite these hurdles, many creative and promising strategies are on the horizon. We review challenges in the development of immunotherapy for T-cell malignancies, strategies to overcome these challenges, as well as therapies currently being investigated and starting to reach the clinic. Immunotherapy will hopefully successfully treat patients with relapsed and refractory T-cell malignancies and may someday be incorporated in up-front protocols in order to prevent relapses. 相似文献